5-Aza-2'-deoxycytidine

Spécifications

2353-33-5Numéro CAS

219-089-4Numéro CE

4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-oneNom IUPAC

C8H12N4O4Formule chimique

228.21 g/molMasse molaire

Decitabine; 5-Aza-2'-deoxycytidine; 2353-33-5; 5-Azadeoxycytidine; 2'-Deoxy-5-azacytidine; 5-Aza-deoxycytidine; Decitabina; 5-AZAdC; NSC 127716; 2-Desoxy-5-azacytidine; DTXSID7030432; NSC-127716; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 776B62CQ27; DTXCID5010432; CHEBI:50131; INQOVI COMPONENT DECITABINE; 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one; s-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-; decitabinum; AzadC compound; Compound, AzadC; 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl)-1,3,5-triazin-2-one; 5 Azadeoxycytidine; 5 Deoxyazacytidine; 5AzadC; 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl)-1,2-dihydro-1,3,5-triazin-2-one; Mesylate, Decitabine; RefChem:57657; 2' Deoxy 5 azacytidine; 5 Aza 2' deoxycytidine; L01BC08; Dacogen; AzadC; Dezocitidine; 5-aza-CdR; MFCD00043011; Dac; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one; MLS001332587; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one; 5-aza-2'-deoxycytidine (Decitabine); SMR000857076; 5-aza-dC; 5-Aza-2'-deoxy Cytidine; 4-amino-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; Alpha-Decitibine; 2-deoxyazacytidine; Dacogen (TN); CAS-2353-33-5; NCGC_5ADOC; Decitabine (USAN/INN); Decitabine [USAN:INN:BAN]; CCRIS 8227; NSC127716; UNII-776B62CQ27; 5-Aza-2'-deoxycytidine;NSC 127716; NCGC00166088-01; 4-Amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2(1H)-one; deoxy-5-azacytidine; EINECS 219-089-4; Decitabine (Standard); BRN 0617982; JNJ 30979754; JNJ-30979754; DECITABINE [MI]; 2'-Deoxy-5-azacytidin; DECITABINE [INN]; DECITABINE [USAN]; 2'-deoxy-5-aza-cytidine; DECITABINE [VANDF]; MolMap_000063; E-7373; DECITABINE [MART.]; SCHEMBL4006; DECITABINE [WHO-DD]; 5-Aza-2'-deoxy-D-cytidine; MLS001332588; MLS006010136; ASTX-727; cid_451668; Decitabine - Bio-X trade mark; GTPL6805; orb1308400; CHEMBL1201129; DECITABINE [ORANGE BOOK]; SCHEMBL27887698; BDBM96274; HY-A0004R; EX-A961; XAUDJQYHKZQPEU-KVQBGUIXSA-N; HMS2235O03; HMS3413L07; HMS3677L07; 105597-46-4; 22432-95-7; HY-A0004; 5-Aza-2'-deoxycytidine, >=97%; Tox21_112311; ASTX727 COMPONENT DECITABINE; EBC-00686; HB1356; AKOS015895047; ASTX-727 COMPONENT DECITABINE; Inqovi (decitabine + cedazuridine); Tox21_112311_1; AC-1135; CCG-208143; CS-0372; DB01262; NA02969; 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-; ASTX727 (decitabine + cedazuridine); Decitabine (NSC127716; 5AZA-CdR); NCGC00166088-02; NCGC00166088-03; NCGC00166088-05; AS-17558; BA164359; SY028608; DB-029060; A9603; SW218076-2; D03665; EN300-269341; AB00918337-07; AB00918337_08; F387707; SR-01000838879; Q1181878; SR-01000838879-4; BRD-K79254416-001-21-8; BRD-K79254416-001-22-6; 5-Aza-2'-deoxycytidine Dacogen 2'-Deoxy-5-azacytidine; Z2467077030; 4-Amino-1-(2-deoxy-b-D-ribofuranosyl)-1,3 ,5-triazin-2(1H)-one; 1,3, 5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy--D-erythro-pentofuranosyl)-; 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-|A-D-erythro-pentofuranosyl)-; 4-AMINO-1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-S-TRIAZIN-2(1H)-ONE; 4-Amino-1-(2-deoxy-beta-D-erythro-pento furanosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-EC-D-erythro-pento furanosyl)-1,3,5-triazin-2(1H)-oneSynonymes